Artelo Biosciences, Inc. (ARTL)
| Market Cap | 1.05M -59.8% |
| Revenue (ttm) | n/a |
| Net Income | -12.67M |
| EPS | -102.42 |
| Shares Out | 547.77K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,649 |
| Open | 2.050 |
| Previous Close | 2.115 |
| Day's Range | 1.910 - 2.226 |
| 52-Week Range | 1.910 - 179.189 |
| Beta | -0.01 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 20, 2026 |
About ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company’s product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and inso... [Read more]
Financial Performance
Financial StatementsNews
Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Nonclinical studies demonstrated reductions in two key measures of neuropathic pain Ongoing Phase 2 CAReS trial includes pain endpoints to evaluate ART27.13's potential to address multiple cancer-rela...
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world's largest gathering of pain professionals
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Presentation to feature results from first clinical study of ART26.12 and highlight the potential of FABP5 inhibition across multiple indications
Why Is Penny Stock Artelo Biosciences (ARTL) Up Over 200% Today?
Artelo Biosciences stock underwent a massive rally after it posted a patent update for a weight-loss drug candidate.
Artelo Biosciences files new provisional patent application covering ART27.13
Artelo Biosciences (ARTL) announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity. The application covers ART27.13 both as a monotherapy and…
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks
Artelo Biosciences announces results from nonclinical study of ART27.13
Artelo Biosciences (ARTL) announced results from a nonclinical study of ART27.13, its oral, once-daily, peripherally selective dual cannabinoid receptor agonist, in the diet-induced obesity model wide...
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
Artelo Biosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Three clinical-stage drug candidates targeting cancer anorexia, glaucoma, pain, and anxiety showed strong interim results, robust safety, and patent protection. Phase II data for cancer anorexia revealed significant weight gain and improved quality of life, with glaucoma trial results expected soon.
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signa...
Artelo Biosciences Slides: Corporate presentation
Artelo Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
Artelo Biosciences Inc trading halted, news pending
19:50 EDT Artelo Biosciences (ARTL) Inc trading halted, news pending
Artelo Biosciences announces 1-for-9 reverse stock split
Artelo Biosciences (ARTL) announced a 1-for-9 reverse stock split of the company’s common stock. The company’s common stock will begin trading on a split-adjusted basis on Nasdaq commencing at the…
Artelo Biosciences Announces Reverse Stock Split
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
Artelo secures Japan patent allowance for ART27.13 commercial formulation
Artelo Biosciences (ARTL) announced that the Japanese Patent Office has issued a notification of allowance with a decision to grant for the company’s patent application covering the intended commercia...
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signal...
Artelo Biosciences receives notice of allowance from USPTO
Artelo Biosciences (ARTL) announced that the United States Patent and Trademark Office has issued a notice of allowance for a U.S. patent application covering the intended commercial formulation of AR...
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo ...
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
SOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signali...
Artelo Biosciences Quarterly report: Q2 2026
Artelo Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Artelo Biosciences Earnings release: Q2 2026
Artelo Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Artelo Biosciences doses first patient in DREAM study
Artelo Biosciences (ARTL) announced the first patient has been dosed in the DREAM study, which will evaluate the effects of Artelo’s orally administered synthetic cannabinoid, ART27.13, in patients wi...
Artelo Biosciences Transcript: AGM 2026
The meeting covered director elections, an increase in authorized shares, and approval for a significant equity issuance. All proposals passed, and no questions were raised by shareholders during the Q&A session.
Artelo Biosciences announces new ART26.12 data
Artelo Biosciences (ARTL) announced new data supporting the therapeutic potential of ART26.12, its proprietary and selective fatty acid binding protein 5 inhibitor, as a novel product candidate for th...
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain Management Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain...